INCY News and Press, Incyte Corporation From 06/20/21

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Big Tech will be in the spotlight next with the U.S. House Judiciary Committee expected to vote on a package on antitrus...

The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY) , is coming off s...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holdi...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holding ...

-- First presentation of long-term safety and disease control data from Phase 3 TRuE-AD studies of ruxolitinib cream in atopic dermatitis Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical ...

The Biotech industry has been working to develop cancer treatments for a long time. But now, with tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca (AZN), Amgen (AMGN), Incyte (INCY), and Champions Oncol...

Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) action date h...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi ® ) for the treatment of adult and pediatric patients 12 years and older with steroid-re...

According to new three-year follow-up data disclosed by Incyte ([[INCY]] +0.6%) and MorphoSys US ([[MOR]] +6.2%), tafasitamab (Monjuvi) and lenalidomide combination has improved patient outcomes in a Phase 2 trial for relapsed or refractory diffuse large B-cell lymphoma ((DLBCL)).The single a...

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (NASDAQ:MOR), and Incyte (NASDAQ:I...